Open Access Open Access  Restricted Access Subscription or Fee Access

Induced Pluripotent Stem Cells: Inventors turning into competitors

Pratap Devarapalli, Swapnil Laxman Bhalke, Neelam Sudhir Dharmadhikari, Vandana Mishra, Neha Mago, Nishad Deshpande, Rajkumar Hirwani


Induced Pluripotent Stem Cells (IPSCs) are a kind of adult cells that have been genetically reprogrammed to become different cell types. Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear contents into oocytes or by fusion with embryonic stem cells. IPSCs technology was pioneered by Shinya Yamanaka from Kyoto University. This breakthrough has inspired researchers to start working around IPSC technology. James Thomson from University of California has developed IPS cell lines derived from Human Somatic Cells. Subsequently, he also established a large scale human IPSC manufacturing company named Cellular Dynamics International. Thus, increasing interest in the commercial exploitation of IPSCs patents has lead us to look into the patent portfolios of top three patent assignees in IPSC technology. In this study, we have discussed technological patent trends and multiple factors which reflect the competitive scenario between the top assignees of IPSC technology. Our conclusions suggest that Kyoto University led by inventor Shinya Yamanaka is the leader of IPSC technology. However, patent-product linkage analysis suggests that Cellular Dynamics International led by inventor James Thomson may surpass Kyoto University in near future.


IPSC; Induced Pluripotent Stem Cells; Patents; Competitive Intelligence

Full Text:



Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676.

Yamanaka, S., & Takahashi, K. (2011). Oct3/4, Klf4, c-Myc and Sox2 produce induced pluripotent stem cells. US8058065 B2. Washington D. C: United States Patent and Trademark Office.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872.

Okita, K., Ichisaka, T., & Yamanaka, S. (2007). Generation of germline-competent induced pluripotent stem cells. Nature, 448(7151), 313-317.

Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., & Thomson, J. A. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science, 318(5858), 1917-1920.

Smith, D. (2010). Commercialization challenges associated with induced pluripotent stem cell-based products. Regenerative medicine, 5(4), 593-603.

Park, I. H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., & Daley, G. Q. (2008). Disease-specific induced pluripotent stem cells. Cell, 134(5), 877-886.

Brinn, M. W., Fleming, J. M., Hannaka, F. M., Thomas, C. B., & Beling, P. (2003, April). Investigation of forward citation count as a patent analysis method. In Systems and Information Engineering Design Symposium, 2003 IEEE (pp. 1-6). IEEE.

Yu, J., Chau, F. K., Jiang, J., Jiang, Y., & Vodyanyk, M. A. (2013). U.S. Patent No. 8,481,317. Washington, DC: U.S. Patent and Trademark Office.

Cost, G. J., Holmes, M. C., Kasahara, N., Laganiere, J., Miller, J. C., Paschon, D., & Zhang, L. (2015). U.S. Patent No. 9,222,105. Washington, DC: U.S. Patent and Trademark Office.

Neuhäusler, P., & Frietsch, R. (2013). Patent families as macro level patent value indicators: applying weights to account for market differences. Scientometrics, 96(1), 27-49.


  • There are currently no refbacks.